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How to estimate treatment effects from reports 
of clinical trials. I: Continuous outcomes
Robert D Herbert
The University of Sydney
Properly conducted randomised trials can aid clinical decision-making by providing unbiased estimates of the
average size of treatment effects. This paper, the first of two, discusses how readers of clinical trials can
extract simple estimates of treatment effect size from trial reports when trial outcomes are measured on a
continuous scale. When making decisions about therapy for individual patients, these estimates can be
modified on the basis of patient characteristics. Modified estimates of treatment effect size can be used to
determine if the effect of treatment is likely to be large enough to be “clinically worthwhile”. This approach
optimises clinical decision-making by combining unbiased estimates of the size of treatment effect from
clinical trials with clinical intuition and patient preferences. [Herbert RD (2000): How to estimate treatment
effects from reports of clinical trials. I: Continuous outcomes. Australian Journal of Physiotherapy
46: 229-235]
Key words: Confidence Intervals; Decision-Making; Evidence-Based Medicine
Introduction
Randomised controlled trials and systematic reviews
of randomised controlled trials potentially provide
unbiased and precise estimates of the effects of
therapy. For this reason they can be used, when
available, as arbiters of which interventions are
effective and which are not.
Unfortunately not all clinical trials are valid, and the
implications of valid trials are not always apparent in
trial reports. Consequently, if readers of clinical trials
are not to be misled, they must critically appraise trial
reports to determine if the findings of the trials are
likely to be valid and to ascertain what the trials
mean. The process of determining the validity of a
trial has been described in many publications (eg
Guyatt et al 1993, Sackett et al 1998), and involves
deciding if the trial satisfies key methodological
criteria such as proper randomisation, adequate
blinding and sufficient follow-up. The purpose of the
present paper is to consider some issues related to the
interpretation of valid clinical trials. Specifically, it
will consider how readers can determine from a trial
report if the effects of a treatment are likely to be
large enough to be worthwhile. These issues have also
been discussed elsewhere (Guyatt et al 1994,
McAlister et al 2000, Sackett et al 1998) although
they have received little attention in the
physiotherapy literature.
Why do we need to know about the
magnitude of a treatment’s effects?
In controlled clinical trials, attention is often focused
on the “p value” of the difference between groups.
The p value is used to determine if the difference
between groups is likely to represent a real treatment
effect or could have occurred simply by chance ie “p”
is the probability of the observed difference between
groups occurring by chance alone. A small
probability (conventionally, p < 5 per cent) means
that it is unlikely that the difference would have
occurred by chance alone, so it constitutes evidence
of a treatment effect. Higher probabilities
(conventionally, probabilities ≥ 5 per cent) indicate
that the effect could have occurred by chance alone.
High p values are properly interpreted as a lack of
evidence of a treatment effect.
A consequence of this tortuous logic is to distract
readers from the most important piece of information
that a trial can provide, that is, information about the
magnitude of the treatment’s effects. If clinical trials
are to influence clinical practice, they must determine
more than simply whether the treatment has an effect.
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They must, in addition, ascertain how big the
treatment effect is. Good clinical trials provide
unbiased estimates of the size of a treatment’s effects.
Such estimates can be used to determine if a
treatment has a big enough effect to be clinically
worthwhile.
What is a clinically worthwhile treatment effect? That
depends on the costs and risks of treatment. Costs
most obviously include monetary costs (to the
patient, health provider or state), but they also include
the inconvenience, discomfort and side-effects of the
intervention. If a treatment is to be clinically
worthwhile, its positive effects must exceed its costs,
so it does more good than harm. Clinical trials often
provide information about the size of treatment
effects, but they rarely provide information about the
costs of treatment. Thus the evaluation of whether a
treatment provides a clinically worthwhile effect
usually requires balancing objective information
about benefical treatment effects (provided by
clinical trials) against subjective impressions of the
costs and risks of treatment (necessarily generated by
therapists and patients). 
What can trials tell us about the effects
of treatment?
All treatments have variable effects. Many will have
beneficial effects on some patients and have no effect
or be harmful to others. Thus, strictly speaking, we
cannot talk of “the effect” of a treatment. What useful
information can a clinical trial provide if it cannot tell
us how all patients (or any individual patient) will
respond to treatment? Clinical trials can provide an
estimate of the average effects of treatment.
Fortunately, knowing about the average effects of
treatment is usually the same as knowing about the
most probable effects of treatment - usually they are,
in fact, the same thing. Thus, while clinical trials
cannot tell us what the effect of a treatment will be for
a particular patient, they can tell us what the most
likely effect will be. The same limitation applies to all
sources of information about treatment effects - this
is not a limitation unique to clinical trials. 
A sensible way to use estimates of average treatment
effects provided by clinical trials is to take them as a
best first guess or prior expectation of what the size
of the treatment effect is likely to be. This can then be
modified up or down depending on the characteristics
of the particular patients to whom the therapy is to be
applied. For example, a recent trial by Dean and
Shepherd (1998) showed that two weeks of task-
specific motor training after stroke increased
maximum seated reaching distance by about eight
centimetres. Subjects in the study had had strokes
more than one year previously but did did not have
dementia or receptive aphasia. We might anticipate
bigger effects than those reported by Dean and
Shepherd if training was conducted sooner after
stroke, but less effect when training demented or very
aphasic patients. This approach combines the
objectivity of clinical trials (which provide unbiased
estimates of average effects of therapy) with the
richness of clinical acumen (which may be able to
distinguish between probable good and poor
responders to therapy). Of course, care must be taken
when using clinical intuition to modify estimates of
treatment effects sizes provided by clinical trials. A
conservative approach would be to ensure that the
estimate of treatment effect size is modified
downwards as often as it is modified upwards,
although it may be reasonable to depart from this
approach if the patients in the trial differ markedly, on
average, from the clinical population being treated.
Particular caution ought to be applied when a clinical
trial provides evidence of no effect of therapy. 
Weighing a treatment’s effects against
its costs: is this effect clinically
worthwhile?
The easiest way to make decisions about whether a
treatment has a clinically worthwhile effect is to first
nominate the smallest treatment effect that is
clinically worthwhile. This is a subjective decision
that involves consideration of patients’ perceptions of
both the benefits and costs of treatment. Most
therapists routinely consider the smallest clinically
worthwhile effect when deciding whether or not to
administer a particular treatment. Sometimes
decisions about what is the smallest clinically
worthwhile effect are explicitly negotiated with the
patient.
To illustrate this process, we will consider if the
application of a pneumatic compression pump
produces clinically worthwhile reductions in post-
mastectomy lymphoedema. We might begin by
nominating the smallest reduction in lymphoedema
that would make the costs of the compression therapy
worthwhile. Most therapists, and perhaps even most
patients, would agree that a short course of daily
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compression therapy would be clinically worthwhile
if it produced a sustained 75 per cent reduction in
oedema. Most would also agree that a 15 per cent
decrease was not clinically worthwhile. Somewhere
in between these values lies the smallest clinically
worthwhile effect. This value is best arrived at by
discussion with the particular patients for whom the
therapy is intended. Let us assume for the moment
that a particular patient (or typical patients) considers
that the smallest reduction in oedema that would
make therapy worthwhile is around 40 per cent. 
Does compression therapy produce reductions in
lymphoedema of this magnitude? Perhaps the best
answer to this question comes from a randomised
trial by Dini et al (1998) that compared two weeks (10
days) of daily intermittent pneumatic compression to
advice only. We will use the findings of this trial to
estimate what the effect of compression therapy is
likely to be.
Estimating the size of a treatment’s
effects
The best estimate of the treatment’s effect is simply
the difference in the means (or, in some trials, the
medians) of the treatment and control groups. In the
trial by Dini et al (1988), oedema was measured by
measuring arm circumference at seven locations,
summing the measures, and then taking the
difference of the summed circumference of affected
and unaffected arms (positive numbers indicate that
the affected arm had a larger circumference than the
unaffected arm). After the two-week experimental
period, the oedema was 14.1cm (SD 5.6) in the
control group and 14.2cm (SD 6.0) in the treatment
group. Thus the best estimate of the treatment effect
is that it increases oedema by 0.1cm (as 14.1cm -
14.2cm = -0.1cm). As the level of oedema averaged
about 15.5cm prior to the experimental period, this
corresponds to an increase of oedema of less than 1
per cent (100 x 0.1/15.5). Clearly this treatment effect
is smaller than the smallest clinically worthwhile
effect (which we had decided might be about 40 per
cent). In fact, the treatment effect is slightly in the
wrong direction, as the treated group had very
slightly more oedema than controls. We can
anticipate that, when pressure therapy is applied to
this population in the manner described by Dini et al,
there will be little effect of therapy. Our best guess is
that the effect of therapy will be, on average (ie, most
probably), too small to be clinically worthwhile.
In the example that has just been used, outcomes were
measured in terms of the amount of oedema at the
end of the experimental period. Some trials will,
instead, report the change in outcome variables over
the treatment period. In such trials, the measure of the
size of the treatment’s effect is still the difference of
the means (this time of the difference of the mean
change) in treatment and control groups. 
Estimating uncertainty
Even when clinical trials are well designed and
conducted, their findings are associated with
uncertainty. This is because the difference between
group means observed in the study is only an estimate
of the true effect of treatment derived from the
sample of 80 subjects employed in the study by Dini
et al. The outcomes in this sample, as in any sample,
approximate but do not exactly equal the average
outcomes in the populations which the sample
represents. Thus the size of the treatment effect
reported in the study approximates but does not equal
the true size of the treatment effect. Rational
interpretation of the clinical trial requires
consideration of how good an approximation the
study provides. That is, to properly interpret a study’s
findings, it is necessary to know how much
uncertainty is associated with its results.
The degree of uncertainty associated with the size of
a treatment effect can be described with a confidence
interval (Gardiner and Altman 1989, Sim and Read
1999). Most often the 95 per cent confidence interval
is used. Roughly speaking, this is the range of
treatment effects within which we can be 95 per cent
certain that the true average treatment effect actually
lies. (Note that the confidence interval describes the
degree of uncertainty about the average effect on the
population, not the degree of uncertainty of the effect
on individuals.) The 95 per cent confidence interval
for the difference between means in the trial by Dini
et al extends from -2.9cm to 2.7cm (methods used to
calculate confidence intervals are presented below)
or, if changes in oedema are expressed as a
percentage of initial oedema, from -19 per cent to 17
per cent. This indicates that we can be confident that
the true average effect of pressure therapy lies
somewhere between an increase in oedema of 19 per
cent and a reduction in oedema of 17 per cent. All of
the values encompassed by the 95 per cent
confidence interval are smaller than the smallest
clinically worthwhile effect. Thus we can conclude
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that not only is the best estimate of the magnitude of
the treatment effect less than the smallest clinically
worthwhile effect (-1 per cent < 40 per cent), but also
that no value of the treatment effect that is plausibly
consistent with the findings of this study exceeds the
smallest clinically worthwhile effect. These data
strongly suggest that pressure therapy, at least as
administered by Dini et al, does not produce clinically
worthwhile reductions in lymphoedema.
Some readers will find confidence intervals easier to
interpret if they sketch the confidence intervals on a
“tree” graph, as in Figure 1. The tree graph consists of
a line along which varying treatment effects lie. The
middle of the line represents no effect (difference
between group means of 0). The right end of the line
represents a very good treatment effect (treatment
group mean minus control group mean is a large
positive number) and the left end represents a very
harmful treatment (treatment group mean minus
control group mean is a large negative number). For
any trial, we can draw three variables on this graph
(Figure 2): the smallest clinically worthwhile effect
(in our example this is 40 per cent), the best estimate
of the treatment effect (the difference between group
means from Dini et al’s randomised controlled trial, or
-1 per cent), and the 95 per cent confidence interval
about that estimate (-19 per cent to 17 per cent). The
region to the right of the smallest clinically
worthwhile effect is the domain of clinically
worthwhile treatment effects. The graph for the Dini
trial (Figure 2B) clearly shows that there is not a
clinically worthwhile effect, because neither the best
estimate of the treatment effect, nor any point
encompassed by the 95 per cent confidence interval
lie in the region of a clinically worthwhile effect. 
Living with uncertainty
In the example just used, the treatment effect was
clearly not large enough to be clinically worthwhile.
Sometimes, of course, the effect of treatment is found
to be clearly clinically worthwhile. Often, however,
the results will be less clear. Ambiguity arises when
the confidence interval spans the smallest clinically
worthwhile effect, because then it is plausible both
that the treatment does and does not have a clinically
worthwhile effect (part of the confidence interval is
less than the smallest clinically worthwhile effect and
part of the confidence interval is greater than the
smallest clinically worthwhile effect; either result
could be the true one). For example, Sand et al (1995)
showed that 15 weeks of pelvic floor electrical
stimulation for women with genuine stress
incontinence produced large reductions in urine
leakage (average of 32mL or 70 per cent reduction)
compared with sham stimulation. This result is shown
on a tree plot in Figure 2B. The mean difference
suggests a large and worthwhile treatment effect, but
the 95 per cent confidence interval spanned from a 7
per cent to a 100 per cent reduction. There is,
therefore, a high degree of uncertainty about how big
the effect actually is and, because the lower end of the
confidence interval includes trivially small reductions
in urine loss, it is not certain, on the basis of this trial
alone, that the therapy is worthwhile.
This situation, when the confidence interval spans the
smallest worthwhile effect, arises commonly for two
reasons. First, the designers of most clinical trials use
sample sizes that are sufficient only to rule out a
treatment effect of zero if there truly is a clinically
worthwhile effect, but such samples may be too small
to prevent their confidence intervals spanning the
smallest clinically worthwhile effect. Second, many
treatments have modest effects (their true effects are
close to the smallest clinically worthwhile effect), so
their confidence intervals must be very narrow if they
are not to span the smallest clinically worthwhile
effect. Consequently, few studies provide
unambiguous evidence of a treatment effect or lack of
treatment effect.
There are two ways to respond to the uncertainty that
is often provided by single trials. First, we can accept
uncertainty and proceed on the basis of the best
available evidence. In this approach, clinical
decisions are based on the difference between group
Figure 1. “Tree plots” of effect size. The tree plot consists of
a horizontal line representing treatment effect. At the
extremes are very harmful and very effective treatments.
The smallest clinically worthwhile effect is represented as a
vertical broken line. The region to the right of this line
(shaded) represents clinically worthwhile effects.
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means. When the difference exceeds the smallest
clinically worthwhile effect, the treatment is thought
to be worthwhile and when the difference between
group means is less than the smallest clinically
worthwhile effect, the treatment is thought to be
insufficiently effective. With this approach, the role of
confidence intervals is to provide an indicator of the
degree of self-doubt that should be applied, but they
do not otherwise affect clinical decisions. An
alternative is to seek certainty by determining if the
findings of individual studies are replicated in other,
similar studies. This is one of the main reasons why
systematic reviews of randomised controlled trials
have become popular (Chalmers and Altman 1995).
In systematic reviews, the results of individual trials
can be combined statistically in a meta-analysis,
effectively providing a single result from many
studies. The combined result is derived from a
relatively large sample size, so it usually provides a
more precise estimate of treatment effect size (its
confidence intervals are relatively narrow), and it is
more likely to provide unambiguous information
about the size of the treatment effect (narrow
confidence intervals are less likely to span the
smallest clinically worthwhile effect). One example is
the systematic review and meta-analysis by Zhang et
al (1996) which showed that primiparous women who
received professional support during labour had
shorter labours than women who received no support
(mean pooled difference 2.8 hours, 95 per cent CI 2.2
to 3.4). This effect (illustrated on a tree plot in Figure
2C) is large, and the confidence intervals are
sufficiently narrow that even the most pessimistic
interpretation of the data (support reduces labour time
by over two hours) suggests a clinically worthwhile
effect.
Calculating confidence intervals for
differences between means
When confidence intervals about differences between
group means are not explicitly supplied in reports of
clinical trials, it is usually an easy matter to calculate
these from the data reported in trials.
The confidence intervals for the difference between
the means for two groups can be calculated from the
difference between the two means (difference), their
standard deviations, and the group sizes. An
approximate 95 per cent confidence interval is given
by first obtaining the average of the two standard
deviations (SD) and the average of the group sizes (n).
Then the 95 per cent confidence interval (95 per cent
CI) is calculated from: 
95 per cent CI = difference  ± 3 x SD / √n
(a derivation of this approximation is given in
Appendix 1). In other words, the confidence interval
spans an interval from 3SD/√n below the difference in
group means to 3SD/ √n above the difference in group
means. This equation is an approximation to the more
complex equation that should be used when triallists
analyse their data, but it is an adequate approximation
for readers of clinical trials to use for clinical
    
Figure 2. (A) Data from Dini et al (1998) on reduction of
oedema. The smallest clinically worthwhile effect has been
nominated as 40 per cent. The best estimate of the size of
the treatment effect (-1 per cent) has been illustrated as a
small square, and the 95 per cent confidence interval about
this estimate (-19 to 17 per cent) is shown as a horizontal
line. The effect is clearly smaller than the smallest clinically
worthwhile effect. (B) Data from Sand et al (1995) on
reduction in urine leakage. The smallest clinically
worthwhile effect has been nominated as 40 per cent. The
best estimate of the size of the treatment effect (70 per
cent) and the 95 per cent confidence interval about this
estimate (7 to 100 per cent) are shown. The best estimate
of the treatment effect is that it is clinically worthwhile, but
this conclusion is subject to a high degree of uncertainty.
(C) Data from Zhang et al (1996) on reduction in labour
time. The smallest clinically worthwhile effect has been
nominated as 1 hour. The best estimate of the size of the
treatment effect (2.8 hours) and the 95 per cent confidence
interval about this estimate (2.2 to 3.4 hours) are shown.
This treatment clearly has a clinically worthwhile effect.
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decision-making. It has the advantage that it is simple
enough to be routinely calculated whenever a clinical
trial does not report the confidence interval for the
difference between group means.
In the trial by Dini et al on 80 subjects (average group
size of 40) the authors reported mean measures of
oedema for both treatment and control groups
(14.2cm and 14.1cm respectively), and the SDs about
those means (6.0cm and 5.6cm respectively; the
average of these two SDs is 5.8cm), but they did not
report the 95 per cent confidence interval for the
difference between means. The 95 per cent
confidence interval can be calculated from this data
and is:
95% CI ≈ (14.1 - 14.2) ± 3 x 5.8 / √40
≈ -0.1 ± 2.8
≈ -2.9 to + 2.7cm
Often papers will report standard errors (SEs) rather
than SDs. In that case, the approximation is even
simpler:
95% CI ≈ difference ± 3 x SE
Many trials have more than two groups (as there may
be more than one treatment group, or more than one
control). The reader must then decide which between-
groups comparison is (or are) of most interest, and
then the 95 per cent confidence intervals for
differences between these groups can be calculated in
the same way as above. Similarly, most trials report
several, and sometimes many, outcomes. It is tedious
to calculate 95 per cent confidence intervals for all
outcomes, and the best approach is usually to decide
which few outcomes are of greatest interest, and then
calculate 95 per cent confidence interval for those
outcomes only. 
Sometimes a degree of detective work is required to
find the SDs or SEs of the group means. If the SD or
SE are not explicitly given they may sometimes be
obtained from the error bars in figures. In other trial
reports, there may be inadequate reporting of trial
outcomes and it will not be possible to calculate 95
per cent confidence intervals. Such trials are difficult
to interpret. Some trials report medians and
interquartile ranges (or other measures of central
tendency and dispersion) instead of means and SDs
and it usually will not be possible to calculate
confidence intervals for these trials.
The procedures described above for calculating the
confidence interval of the difference between two
means will tend to produce overly conservative
confidence intervals (confidence intervals that are
too broad) in some circumstances. In particular, this
procedure will tend to produce confidence intervals
that are too broad when the study is a cross-over
study, a study in which subjects are matched prior to
randomisation, or a study in which statistical
procedures are used to partition out explainable
sources of variance (such as ANCOVA). Less often, if
the sample size is small and the group sizes are very
unequal, the confidence interval may be too narrow.
In such studies it is highly desirable that the authors
report confidence intervals for the differences
between groups. Unless authors provide confidence
intervals for differences between groups it usually
will not be possible for the reader to obtain more
accurate estimates of the 95 per cent confidence
intervals.
The next paper in this two-part series will describe
how to determine the size of a treatment’s effects on
dichotomous outcomes. 
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Appendix.
Approximate 95 per cent confidence intervals for the difference between two means
The usual equation for the confidence interval about the difference between two means is:
CI = difference ± t
(1-a/2)
x (nt - 1) SDt
2 + (n
c
- 1) SD
c
2 x 1     1
where difference is the difference between group means, t
(1-a/2)
is the appropriate value from a 
t-distribution, n is the number of subjects and SD is the standard deviation in a group, and the subscripts t and c
mean “of the treatment group” and “of the control group” respectively (Gardner and Altman 1989). In
randomised clinical trials the group sizes are usually similar (i.e. n
t
≈ n
c
) and it is usually assumed that the
variances are equal (so that SD
t
= SD
c
). When n
t
= n
c
= n, and SD
t
= SD
c
= SD, these expressions simplify to:
CI = difference ± t
(1-a/2)
x √2 x SD / √n
As t
(1-a/2)
for the 95 per cent CI ≈ 2, and √2 ≈ 1.5, this simplifies further to:
95 per cent CI ≈ difference ± 3 x SD / √n
The adequacy of this approximation was tested by comparing the width of the confidence intervals produced with
“exact” and approximate equations using group sizes of between 10 and 100 subjects and effect sizes (expressed
here as the inverse of the SD of the difference between group means) of 0.2 to 0.8. The approximate equation
tended to produce confidence intervals that were too wide, but the magnitude of this error was always less than
8 per cent. This was so even when n
t
and n
c
or SD
t
and SD
c
differed by 20 per cent. The mean absolute error was
5 per cent. These small and conservative errors are probably acceptable for clinical decision-making.
n
t
+ n
c
- 2 nt + nc
